LEIBER-X™
Single-cell Intelligence as a Service
Accelerate clinical success through cellular-level patient intelligence platform
Transform $50 bulk RNA-seq into $4,000+ single-cell resolution profiles with explainability, reproducibility, and audit trails that validators trust
GRN + CNV Explainability
Gold-standard Reproducibility
Audit-ready Traceability
100K+ Archives Reactivated
<4 Week Pilots
Validator Sign-off
CDx Champion Enablement
3-Tier Pricing
Virtual Cell Architecture
Transforming bulk data into single-cell precision through AI-powered deconvolution
Single-Cell Core
Data Foundation
WittGen single-cell database with 1.3B+ cells provides the ground truth for all platform capabilities.
Bulk-to-Single Cell GenAI
Affordable Single-Cell Resolution
Transform $50 bulk RNA-seq into $4,000+ single-cell resolution profiles with cellular-level precision.
Image-to-Omics
Image2SC Capability
Derive single-cell omics insights from imaging data to expand analytical capabilities.
Continuous Value Across Clinical Phases
From historical data analysis through trial design, patient screening, and outcome analysis
Superior Data Quality = Superior Results
Our data-centric AI approach prioritizes quality over quantity. Well-curated datasets with precise annotation deliver significantly better model performance.
95% ML Accuracy
vs. 70% market standard
Our Competitive Edge
- CNV inference scoring for cell-level validation
- Manual expert curation + extra information mining
- Golden standard reference dataset construction
- Automated annotation pipeline for scale
UMAP Representation
Real vs Generated Cell Distributions
PDAC (Test Information)
(Image placeholder - add /assets/images/b2sc-pdac-real.png)
Real Data
(Image placeholder - add /assets/images/b2sc-pdac-generated.png)
Generated Data
(Image placeholder - add /assets/images/b2sc-pdac-comparison.png)
Real vs Generated
Virtual Cell Model maintains high performance in complex cancer datasets, scoring MMD ≈ 0.7 / WD ≈ 10.6
The Virtual Cell GenAI Pipeline
From your bulk RNA archives to regulator-ready patient stratification—here's how our platform transforms your data into actionable insights.
Input
Bulk RNA Archives
$50 runs, FFPE, and historical datasets you already trust. We handle QC, harmonization, PHI guardrails, and metadata normalization automatically.
Output
Regulator-Ready Strat Plans
Single-cell clarity on cohorts, responder predictions, biomarker packages, and documentation that Bioinformatics validators and regulators can sign off on.
What WittGen Delivers
Retrospective Pilot
We convert legacy bulk RNA-seq into single-cell clarity for one priority program, deliver cohort guidance, and prove uplift before you commit to wet-lab.
Validator Evidence Pack
Explainability • Reproducibility • Traceability documentation for Bioinformatics and regulatory reviewers, including GRN/CNV narratives and model cards.
Pipeline Expansion Kit
Playbooks, APIs, and CDx/Innovation champion tooling so you can run multiple programs in parallel (Pipeline + Platform tiers).
Faster Predictions
Virtual patient responses before actual dosing accelerates decision-making.
More Insights
Biomarkers at cellular level (TME/rare cell populations) unlock hidden opportunities.
Boost Success Rates
Identify responder populations with 7x higher precision through cellular-level profiling.
Cost Reduction
$50 bulk RNA-seq achieves 95% savings versus traditional $4,000+ single-cell methods.
See How We Fixed Stratification
Read how innovation teams, CDx partners, and bioinformatics validators aligned on WittGen output before moving to pipeline and platform tiers.
View Portfolio